The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life

Journal of Acquired Immune Deficiency Syndromes

Volumn 47, Issue 2, 2008, Pages 185-193

  Burman, William J ^a   Grund, Birgit ^b   Roediger, Mollie P ^c   Friedland, Gerald ^d   Darbyshire, Janet ^e   Wu, Albert W ^f  

^a DENVER PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MRC CLINICAL TRIALS UNIT   (United Kingdom)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiretroviral therapy; Quality of life; Randomized trial; Symptoms; Treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; HEALTH STATUS; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIAL STATUS; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS LOAD; VISUAL ANALOG SCALE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 38649088253     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31815acaa4     Document Type: Article

References (26)

1. Dieleman JP, Jambroes M, Gyssens IC, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS. 2002;16:737-745.
2. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet. 2001;358:1322-1327.
3. Ickovics JR, Cameron A, Zackin R, et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther. 2002;7:185-193.
4. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445-449.
5. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
6. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-598.
7. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis. 2002;34:838-846.
8. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
9. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115-1121.
10. Gardner EM, Burman WJ, Maravi ME, et al. Durability of adherence to antiretroviral therapy on initial and subsequent regimens. AIDS Patient Care STDS. 2006;20:628-636.
11. Tuldra A, Fumaz CR, Ferrer MJ, et al. Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads. AIDS. 2001;15:1904-1906.
12. Hogg RS, Havlir D, Miller V, et al. To stop or not to stop: that is the question, but what is the answer? AIDS. 2002;16:787-789.
13. Lori F, Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JAMA. 2001;286:2981-2987.
14. The SMART Study Group. CD 4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
15. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233.
16. Wu AW, Huang IC, Gifford AL, et al. Creating a crosswalk to estimate AIDS Clinical Trials Group quality of life scores in a nationally representative sample of persons in care for HIV in the United States. HIV Clin Trials. 2005;6:147-157.
17. Table for Grading Severity of Adult Adverse Experiences. August 1992. Updated by DAIDS in 1997 for use by the CPCRA trials network. Available at: http://rcc.tech-res.com/tox_tables.htm. 2006. Accessed October 16, 2007.
18. Ware JE, Kosinski M, Turner-Bowker DM, et al. How to Score the SF-12 Physical and Mental Summary Scales. 2nd ed. Boston, MA: The Health Institute-New England Medical Center; 1995.
19. Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. How to Score Version 2 of the SF-12® Health Survey (with a supplement documenting version 1). Lincoln, RI: Quality Metric; 2005.
20. Wu AW, Rubin HR, Mathews WC, et al. Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection. J Acquir Immune Defic Syndr. 1993;6:452-458.
21. Zinkernagel C, Ledergerber B, Battegay M, et al. Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study. AIDS. 1999;13:1587-1589.
22. Powers AE, Marden SF, McConnell R, et al. Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection. AIDS. 2006;20:837-845.
23. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2004. Atlanta, GA: Centers for Disease Control and Prevention; 2005:1-46.
24. Cohen C, Revicki DA, Nabulsi A, et al. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. AIDS. 1998;12:1495-1502.
25. Casado A, Consiglio E, Podzamczer D, et al. Highly active antiretroviral treatment (HAART) and health-related quality of life in naive and pretreated HIV-infected patients. HIV Clin Trials. 2001;2:477-483.
26. Nieuwkerk PT, Gisolf EH, Colebunders R, et al. Quality of life in asymptomatic- and symptomatic HIVinfected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group. AIDS. 2000;14:181-187.